Induction of neutralizing antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors

Vaccine

Volumn 24, Issue 42-43, 2006, Pages 6513-6525

  Khanam, Saima ^a   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Adenovirus; Dengue vaccine; Dengue 2; Envelope domain III; Plasmid

Indexed keywords

ADENOVIRUS VECTOR; DENGUE VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; PLASMID VECTOR; VIRUS ENVELOPE PROTEIN;

ANALYTICAL PARAMETERS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE; DENGUE VIRUS; DRUG EFFICACY; DRUG POTENCY; EMBRYO; EXPRESSION VECTOR; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL; T LYMPHOCYTE; TH1 CELL; VACCINATION; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRION; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS STRAIN;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOKINES; DENGUE VIRUS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENETIC VECTORS; HEMOLYTIC PLAQUE TECHNIQUE; LIPIDS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 33749442006     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.031     Document Type: Article

References (42)

1. Lindenbach B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Field's virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia, PA 991-1041
2. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 (2002) 100-103
3. Guzmán M.G., and Kouri G. Dengue: an update. Lancet Infect Dis 2 (2002) 33-42
4. Rothman A.L. Dengue: defining protective versus pathologic immunity. J Clin Invest 113 (2004) 946-951
5. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull WHO 83 (2005) 308-314
6. Halstead S.B., and Deen J. The future of dengue vaccines. Lancet 360 (2002) 1243-1245
7. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, et al. Meeting report: review on flavivirus vaccine development: proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health, Bangkok, Thailand, April 26-27, 2004. Vaccine 2005;23:2689-95.
8. Kanesa-thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19 (2001) 3179-3188
9. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am J Trop Med Hyg 66 (2002) 264-272
10. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three-dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 (2004) 99-109
11. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trials of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 (2003) 48-60
12. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24 (2006) 1238-1241
13. Swaminathan S., and Khanna N. Viral vaccines for dengue: the present and the future. WHO Dengue Bull 27 (2003) 181-191
14. Jaiswal S., Khanna N., and Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type-2. J Virol 77 (2003) 12907-12913
15. Mégret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology 187 (1992) 480-491
16. Crill W.D., and Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75 (2001) 7769-7773
17. Roehrig J.T., Bolin R.A., and Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus. Jamaica Virol 246 (1998) 317-328
18. Kuhn R.J., Zhang W., Rossman M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 (2002) 717-725
19. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3 (1997) 866-871
20. Hung J.J., Hsieh M.-T., Young M.-J., Kao C.-L., King C.-C., and Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78 (2004) 378-388
21. Jaiswal S., Khanna N., and Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type-2 envelope domain III protein in Escherichia coli. Protein Exp Purif 33 (2004) 80-91
22. Thullier P., Demangel C., Bedouelle H., Mégret F., Jouan A., Deubel V., et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82 (2001) 1885-1892
23. Mota J., Acosta M., Argotte R., Figueroa R., Méndez A., and Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 (2005) 3469-3476
24. Simmons M., Nelson W.M., Wu S.J.L., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58 (1998) 655-662
25. Simmons M., Murphy G.S., and Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65 (2001) 159-161
26. Hermida L., Bernardo L., Martín J., Alvarez M., Prado I., López C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 (2006) 3165-3171
27. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.-X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
28. Yang Z.-Y., Wyatt L.S., Kong W.-P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77 (2003) 799-803
29. He T.-C., Zhou S., DaCosta L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 (1998) 2509-2514
30. Buchmann M., Swaminathan S., and Thimmapaya B. Regulation of cellular genes in a chromosomal context by the retinoblastoma tumor suppressor protein. Mol Cell Biol 18 (1998) 4565-4576
31. Khanam S., Etemad B., Khanna N., and Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these serotypes. Am J Trop Med Hyg 74 (2006) 266-277
32. Bisht H., Chugh D.A., Swaminathan S., and Khanna N. Expression and purification of dengue virus type 2 envelope protein as a fusion with Hepatitis B surface antigen in Pichia pastoris. Protein Exp Purif 23 (2001) 84-96
33. Anderson L.M., Swaminathan S., Zackon I., Tajuddin A.-K., Thimmapaya B., and Weitzman S.A. Adenovirus mediated tissue-targeted expression of the HSV-tk gene for the treatment of breast cancer. Gen Ther 6 (1999) 854-864
34. Trirawatanapong T., Chandran B., Putnak R., and Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116 (1992) 139-150
35. AnandaRao R., Swaminathan S., Fernando S., Jana A.M., and Khanna N. A custom-designed recombinant multiepitope protein as a dengue diagnostic reagent. Protein Exp Purif 41 (2005) 136-147
36. Konishi E., Kosugi S., and Imoto J.-I. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 (2006) 2200-2207
37. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24 (2006) 335-344
38. Shiver J.W., and Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann Rev Med 55 (2004) 355-372
39. Gaydos C.A., and Gaydos J.C. Adenovirus vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), W.B. Saunders Co., Philadelphia 609-628
40. Ramshaw I.A., and Ramsay A.J. The prime-boost strategy: exciting prospects for improved vaccination. Trends Immunol Today 21 (2000) 163-165
41. Putnak R.P., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., and Hoke C. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 45 (1991) 159-167
42. Delenda C., Staropoli I., Frenkiel M.P., Cabanié L., and Deubel V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75 (1994) 1569-1578